Report on Annual General Meeting held in NeuroSearch A/S

4/10/2012 12:24 PM EST

NeuroSearch A/S
Decisions of annual general meeting

Report on Annual General Meeting held in NeuroSearch A/S

Announcement
10.04.2012


At the company's Annual General Meeting today, the following decisions were
taken by the general meeting: 


  -- The 2011 Annual Report and the Board of Director’s proposal regarding the
     transfer of profits and losses for 2011 to next year were adopted.
     
  -- The Board of Directors was re-elected and thus still consists of Thomas
     Hofman-Bang (Chairman), Allan Andersen, Torbjörn Bjerke, Anders Ullman, Ian
     Talmage and the following newly elected employee representatives: Carsten
     Jessen, Janus Schreiber Larsen and Lars Siim Madsen.
     
  -- PricewaterhouseCoopers was re-elected as the company's auditor.
     
  -- The Board withdrew its proposal regarding the possibility of using
     electronic communication between the company and its shareholders.
     
  -- The Board's proposed change to the remuneration policy for the Board of
     Directors and Executive Management was adopted.
     
  -- The proposed fee to the Board of Directors for 2012 was approved. 
     
  -- The general meeting authorised the Board to purchase own shares of up to a
     total nominal value of DKK 2,455,394 (corresponding to 10% of the company's
     present share capital) in the period until the next Annual General Meeting.


Patrik Dahlen
CEO


Contact persons:
Patrik Dahlen, CEO, telephone: +45 2629 7296
René Schneider, EVP & CFO, telephone: +45 2911 2097


About NeuroSearch
NeuroSearch is a European-based biopharmaceutical company specialising in CNS
diseases. The company is listed on NASDAQ OMX Copenhagen A/S. The company’s
product pipeline comprises Huntexil® for the treatment of motor symptoms in
patients with Huntington's disease and ordopidine and seridopidine, which have
both completed Phase I development. Huntexil® is currently in Phase III
development. The overall objective for NeuroSearch is to create a profitable,
specialty pharma company building on the platform the company will achieve from
a successful development and marketing of Huntexil®. The company also has a
portfolio of assets for outlicensing or divestment.